Sequenom diagnostic news

Sequenom will reduce headcount by about 30 (12%) to 220 to reduce costs and focus on its SEQureDx technology. The cuts will be in the company's genetic analysis business unit. The SEQureDx technology includes the SEQureDx Down Syndrome test, which was expected to launch in June, but has been postponed due to "employee mishandling" of data. The company plans to submit a PMA for the test in 2H10. Sequenom's Rhesus D, cystic fibrosis (CF) and FetalXY tests, which also use the SEQureDx technology, are expected to launch next quarter. ...